GemPharmatech Co., Ltd. (SHA:688046)

GemPharmatech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	304.33	701.37	560.17	421.71	293.52	524.2
Short-Term Investments	-	109.33	120.1	-	-	-
Trading Asset Securities	894.15	467.34	637.72	791.24	205.8	-
Cash & Short-Term Investments	1,198	1,278	1,318	1,213	499.31	524.2
Cash Growth	-0.98%	-3.03%	8.66%	142.92%	-4.75%	110.53%
Accounts Receivable	426.7	350.81	269.39	185.45	118.57	90.68
Other Receivables	4.86	6.28	6.09	3.63	39.68	0.16
Receivables	431.55	357.09	275.48	189.08	158.25	90.84
Inventory	69.47	54.2	47.09	49.47	30.08	17.32
Prepaid Expenses	-	-	-	-	3.41	-
Other Current Assets	91.8	20.45	16.96	15.51	15.87	14.89
Total Current Assets	1,791	1,710	1,658	1,467	706.93	647.25
Property, Plant & Equipment	654.08	626.28	624.9	375.15	232.78	163.15
Long-Term Investments	111.35	109.05	175.53	306.94	30.08	-
Other Intangible Assets	49.05	49.05	47.34	48.51	49.53	41.2
Long-Term Deferred Tax Assets	41.69	35.98	31.85	17.05	4.81	5.69
Long-Term Deferred Charges	36.42	40.58	36.68	19.29	24.63	23.83
Other Long-Term Assets	146.15	1.94	3.77	19.77	5.66	2.08
Total Assets	2,830	2,573	2,578	2,254	1,054	883.19
Accounts Payable	67.68	72.18	101.86	50.79	61.73	46.31
Accrued Expenses	39.78	57.42	50.94	46.56	39.04	25.35
Short-Term Debt	255.37	88.04	76.16	12.21	5.15	5.02
Current Portion of Leases	14.15	8.82	9.4	2.61	-	-
Current Income Taxes Payable	11.34	2.84	14.89	4.09	6.44	10.7
Current Unearned Revenue	147.8	138.23	108.42	89.15	75.91	60
Other Current Liabilities	6.44	3.68	4.75	8.66	3.47	2.09
Total Current Liabilities	542.56	371.2	366.41	214.07	191.74	149.47
Long-Term Debt	-	-	-	-	20.03	-
Long-Term Leases	57.88	35.62	36.07	3.05	0.02	-
Long-Term Unearned Revenue	18.82	22.9	41.04	48.99	50.49	70.4
Long-Term Deferred Tax Liabilities	9.75	8.2	9.41	9.9	6.5	6.08
Total Liabilities	629.01	437.92	452.93	276	268.78	225.95
Common Stock	410	410	410	410	360	360
Additional Paid-In Capital	1,253	1,261	1,258	1,254	276.73	273.66
Retained Earnings	552.52	487.61	455.4	313.3	148.63	23.71
Treasury Stock	-22.9	-32.67	-	-	-	-
Comprehensive Income & Other	8.17	8.64	1.09	0.91	0.27	-0.12
Total Common Equity	2,201	2,135	2,125	1,978	785.63	657.24
Shareholders' Equity	2,201	2,135	2,125	1,978	785.63	657.24
Total Liabilities & Equity	2,830	2,573	2,578	2,254	1,054	883.19
Total Debt	327.4	132.48	121.62	17.86	25.2	5.02
Net Cash (Debt)	871.09	1,146	1,196	1,195	474.11	519.18
Net Cash Growth	-20.56%	-4.25%	0.11%	152.07%	-8.68%	122.86%
Net Cash Per Share	2.15	2.82	2.94	3.05	1.33	1.43
Filing Date Shares Outstanding	410	407.41	410	410	410	360
Total Common Shares Outstanding	410	407.41	410	410	360	360
Working Capital	1,249	1,339	1,291	1,253	515.19	497.78
Book Value Per Share	5.37	5.24	5.18	4.82	2.18	1.83
Tangible Book Value	2,152	2,086	2,077	1,929	736.1	616.05
Tangible Book Value Per Share	5.25	5.12	5.07	4.71	2.04	1.71
Buildings	-	324.85	311.67	97.08	97.78	93.13
Machinery	-	263.75	229.67	129.2	93.79	69
Construction In Progress	-	90.85	89.6	171.67	53.02	2.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.